Clinical Trial Update: Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer [Phase 2]

View source ↗

Summary

Betta Pharmaceuticals is updating a Phase 2 clinical trial evaluating Befotertinib and Icotinib in treatment-naive patients with advanced EGFR-mutant non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib
• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING